Pyrexar Medical today purchased back all outstanding third party interest in the Utah based corporation.
In April of 2015, Pyrexar Medical purchased the hyperthermia assets from Perseon Medical, which included the BSD-500 Superficial /Interstitial Hyperthermia System and the BSD-2000 Deep Regional Hyperthermia Systems. In the original purchase agreement, Perseon Medical maintained a 19.9% interest in Pyrexar, along with royalties on future product sales.
In an agreement reached today, Pyrexar purchased back all Perseon held interests, including all current and future royalty payments. “With the expected growth of Pyrexar Medical, we felt this was a great opportunity to retain full ownership of the company,” said Pyrexar CEO Mark Falkowski. “We should see a significant return on this investment.”
ABOUT PYREXAR MEDICAL:
Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR Hyperthermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.
To find out more about Pyrexar Medical products, visit our webpage www.pyrexar.com